Kangzhe Pharmaceutical Industry: The new drug DeXeDuSi tabloid for renal anemia has been approved for marketing in China.

Kangzhe Pharmaceuticals announced on March 13 that the market approval application for the new drug Desidustat tablets for renal anemia has been approved by the China National Medical Products Administration on March 13, 2026. This product is an innovative oral hypoxia-inducible factor-prolyl hydroxylase inhibitor, suitable for the treatment of anemia in non-dialysis adult patients with chronic kidney disease.